Utilization of Biosimilars: Achieving Value-Based Plan Management Through Access, Outcomes, and Communication

Utilization of Biosimilars: Achieving Value-Based Plan Management Through Access, Outcomes, and Communication is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Dec 28, 2018 - Dec 28, 2019.

Accreditation:
In support of improving patient care, the National Committee for Quality Assurance (NCQA) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE) and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.?

CME
NCQA designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE
This educational activity is approved for 1 nursing education contact hour.

CPE
This activity is approved for 1 contact hour (.01 CEU) of continuing pharmacy education (UAN JA0004597-0000-18-020-H04-P).

Intended Learners:
This activity is designed for the seasoned health care management professional responsible for managing, implementing and assessing the Health Plan Accreditation survey process and those professionals gathering, analyzing, or reporting HEDIS data.

Learning Objectives:
After completion of this activity, participants should be able to: IVES 
• Highlight the clinical, cost, regulatory, and stakeholder considerations that impact the adoption of biosimilar treatments in the United States
• Review the key clinical and regulatory concepts surrounding biosimilars including totality of evidence, complex data analytics, indication extrapolation, and interchangeability/substitution
• Evaluate the current evidence surrounding biosimilar safety and efficacy, economic, post-approval data, and resources available to improve provider/patient confidence
• Describe how biosimilars complement the evolving landscape of value-based, quality health care
• Initiate strategies to address barriers to biosimilar adoption through formulary, plan, and value-based reimbursement as well as patient/provider communication strategies